OVUM Voices
NewLimit on longevity biotech and women's health
All perspectives
LongevityInvestor POV·Jun 16, 2026
"Longevity biotech is quietly becoming women's health biotech."
— OVUM Editorial on LinkedIn
OVUM context
Ovarian aging is upstream of most female-specific longevity phenotypes. This is the biotech-pharma beat's biggest emerging convergence.
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.